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Is NFκB a good target for cancer therapy? Hopes and pitfalls

Véronique Baud and Michael Karin
Abstract | Nuclear factor κB (NF-κB) transcription factors have a key role in many physiological processes such as innate and adaptive immune responses, cell proliferation, cell death, and inflammation. It has become clear that aberrant regulation of NF-κB and the signalling pathways that control its activity are involved in cancer development and progression, as well as in resistance to chemotherapy and radiotherapy. This article discusses recent evidence from cancer genetics and cancer genome studies that support the involvement of NF-κB in human cancer, particularly in multiple myeloma. The therapeutic potential and benefit of targeting NF-κB in cancer, and the possible complications and pitfalls of such an approach, are explored.
Cancer remains a leading cause of death in industrialized countries 1 . Although mortality rates have declined in recent years owing to earlier detection and the availability of new treatments options, most cancers remain incurable. It is impor tant to stress that cancer is not one but many different diseases, each with distinct characteristics and therapeutic options. The progressive sequence of mutations and epigenetic alterations of cancer genes promotes the malignant transformation of cancer progenitor cells by disrupting key processes that are involved in the control of normal growth and tissue homeostasis 2
. In addition, genomic instability is a common, if not universal, feature of advanced tumours. Therefore, one major challenge for cancer researchers is to distinguish cancercausing mutations from irrelevant alterations linked to complex cancer genotypes.
In addition to such changes that are intrinsic to the malignant cell, tumour develop ment and progression are also depend ent on the microenvironment surrounding the malignant cell, which in many cases are inflammatory in nature 3 . The crucial role played by the inflammatory microenviron ment in the natural history and progression of most cancers offers new opportunities to therapeutic intervention based on targeting the inflammatory components of the tumour rather than the malignant cell, which is quick to mutate and acquire drug resistance 4, 5 . The current anticancer armamentarium includes many active agents that are applied across tumour types. none of these broadly active anticancer drugs is a panacea. Most drugs have a small therapeutic index and barely discriminate between malignant and normal cells -a problem that is further amplified by the almost inevitable onset of resistance and subsequent relapse.
In recent years, the focus has shifted to targeting specific signalling pathways that drive inappropriate cell growth and survival, therefore offering the promise of greater specificity coupled with reduced systemic toxicity. Such strategies rely on new approaches for studying cancer genetics and cancer genomes, such as gene expression profiling using microarrays, DnA sequencing, and genome scanning for gene copynumber alterations [6] [7] [8] [9] [10] [11] [12] [13] . The successful development of a rationally designed, molecularly targeted therapy for the treatment of a specific cancer is best illustrated by the clinical success of the anti HeR2 antibody trastuzumab (Herceptin; Genentech/Roche) for HeR2positive breast cancer 14, 15 , and the smallmolecule kinase inhibitor imatinib (Gleevec; novartis) for the treatment of BCR-ABlpositive chronic myeloid leukemias 16 . In the validation and selection of molecular targets and pathways for therapeutic inter vention in cancer, the frequency with which a particular target or a pathway undergoes mutation or deregulation is a valuable indicator of its importance in the malig nancy process and of the potential uses of a drug that acts on that target or pathway. An important signalling pathway that is often altered in human cancers is the IκB kinase(IKK)/nuclear factor κB (nFκB) signalling module. Aberrant nFκB regula tion has been observed in many cancers, including both solid and haematopoietic malignancies
, and nFκB can affect all six hallmarks of cancer (BOX 1) through the transcriptional activation of genes asso ciated with cell proliferation, angiogenesis, metastasis, tumour promotion, inflamma tion and suppression of apoptosis [17] [18] [19] [20] [21] [22] (FIG. 1) .
Various mouse models of cancer in which IKK/nFκB activation has been blocked by genetic means have highlighted the key role of nFκB as a crucial promoter of inflammationlinked cancers [23] [24] [25] [26] . one of the most documented functions of nFκB is its ability to promote cell survival through the induction of target genes, the products of which inhibit the apoptotic machinery in both normal and malignant cells 20, 27 . nFκB can also prevent pro grammed necrosis by inducing genes that encode antioxidant proteins 27 . As tumour cells often use nFκB to achieve resistance to anticancer drugs and radiation therapy, inhibition of nFκB activation seems to be a promising option to improve the efficacy of conventional anticancer thera pies 28 . However, only recently has cancer genomics proved useful to demonstrate the key role of nFκB in carcinogenesis and to identify vital steps that drive its activation. one difficulty that may have slowed down the realization that nFκB is frequently altered in cancer is that in most cases nFκB is activated in malignant cells in response to inflammatory stimuli originating from the microenvironment, and not because of intrinsic mutations 5 . In other cases, which will be described below, the oncogenic mutations reside in genes that encode upstream regulators of nFκB activity.
The nF-κB family and signalling pathways In mammals, the nFκB family is composed of five members: RelA (p65), RelB, Rel (cRel), nFκB1 (p50 and its precursor p105) and nFκB2 (p52 and its precursor p100) 29 . These proteins form homodimeric and heterodimeric complexes, and the activity of these proteins is regulated by two major pathways. The first -known as the classi cal or canonical nFκB activation pathway -mainly applies to RelA-p50 dimers, which, under nonstimulated conditions, are sequestered in the cytoplasm through interactions with inhibitory proteins of the IκB family. Following stimulation with a broad range of stimuli -such as tumour necrosis factor α (TnFα) or interleukin 1 (Il1), viruses, genotoxic agents and ion izing radiation -the IκB molecules are phosphorylated by the IKK complex at specific serine residues, which leads to their ubiquitylation and degradation by the pro teasome pathway. RelA-p50 dimers are subsequently released and translocate to the nucleus where they activate the transcription of various target genes 30 . This pathway has a major role in the control of innate immunity and inflammation 31, 32 .
The second pathway -the socalled alternative or noncanonical nFκB signal ling pathway -is stimulated by a more restricted set of cytokines that all belong to the TnF superfamily (for example, BAFF (also known as TnFSF13B), lymphotoxin β (lTβ) and CD40 ligand (CD40l)). This pathway involves the upstream kinase nFκBinducing kinase (nIK), which activates IKKα, thereby leading to the phosphorylation and proteasome dependent processing of p100, the main RelB inhibitor, resulting in RelB-p52 and RelB-p50 nuclear translocation and DnA binding [33] [34] [35] [36] [37] . Most importantly, all studies point to a crucial role for the alternative pathway in controlling the development, organization and function of secondary lymphoid organs, and in Bcell maturation and survival 32, 38 . The activation of the canonical as well as the alternative nFκB pathways relies on the inducible phosphorylation of IκB inhibitory proteins (IκBα for the classical pathway and p100 for the alter native pathway) by the IKK complex and its subunits 30 . IKK is composed of two catalytic subunits, IKKα and IKKβ, and a regulatory subunit, IKKγ (also known as neMo). Disruption of genes encoding individual subunits has demonstrated that IKKβ and IKKγ are required for activation of the classical nFκB pathway by inflam matory signals, a pathway in which IKKα does not have an essential role. By contrast, RelB-p50 and RelB-p52 activation is absolutely dependent on IKKα, but not on IKKβ or IKKγ 33, 39 .
Multiple myeloma and nF-κB pathways
The most dramatic and broad example for genetic alterations that lead to activation of nFκB in cancer was recently identified through the application of oncogenomics in multiple myeloma. Multiple myeloma is a Bcell neoplasia that accounts for 1% of all cancers and more than 10% of total haematological malignancies. Multiple myeloma is mainly characterized by the unrestrained accumulation of antibody secreting plasma B cells in the bone marrow, which is attributed to the loss of apoptosis control and cellcycle deregulation [40] [41] [42] . The bonemarrow microenvironment has also been shown to contribute to the pathogenesis and progression of multiple myeloma 43 . Despite advances in chemotherapy and stemcell transplantation, which have improved survival rates, multiple myeloma remains an incurable disease. Therefore, new treatment approaches are needed to improve the outcome of multiple myeloma therapy and provide patients with longer disease free survival. of all the different signalling pathways that are constitutively activated in primary multiple myeloma cells, nFκB has recently emerged as one of the most important drivers of the tumourpromoting machinery.
Biochemical evidence. Constitutive nuclear nFκB activity has been described in many human multiple myeloma cell lines and primary myeloma cells [44] [45] [46] . Furthermore, multiple myeloma cells have been shown to be sensitive to growth inhibition and induction of apoptosis upon treatment with various inhibitors of nFκB signalling. Such compounds include proteasome inhibi tors, inhibitors of IκB phosphorylation and IKK inhibitors [47] [48] [49] [50] [51] . Inhibition of nFκB correlates with a decrease in the expression of known antiapoptotic nFκB target genes. These genes include BCLXL (also known as BCL2L1), Xlinked inhibitor of apop tosis protein (XIAP), cIAP1 (also known as BIRC2) and cIAP2 (also known as BIRC3), as well as proliferative genes, such as IL6 and cyclin D1 (CCND1) 46, 49, 51, 52 . Activation of nFκB in bonemarrow stromal cells (BMSCs) also contributes to the pathogen esis of multiple myeloma. The adherence of multiple myeloma cells to BMSCs induces nFκBdependent cytokine transcription
Box 1 | The hallmarks of cancer
The 'hallmarks of cancer' 2 are: • Self-sufficiency in proliferative growth signals.
• Insensitivity to growth inhibitory signals.
• Evasion of apoptosis.
• Acquisition of limitless replicative potential.
• Induction of angiogenesis.
• Induction of invasion and metastasis.
Box 2 | Human cancers that have been linked to constitutive nF-κB activation
Various haematological malignancies and solid tumours that exhibit constitutive nuclear factor κB (NF-κB) activation are listed below (adapted from REF. 17):
Haematological malignancies. Multiple myeloma, mantle cell lymphoma, MALT lymphoma, diffuse large B-cell lymphoma, Hodgkin's lymphoma, myelodysplastic syndrome, adult T-cell leukaemia (HTLV-1), acute lymphocytic leukaemia, acute myeloid leukaemia, chronic lymphocytic leukaemia and chronic myeloid leukaemia.
Solid tumours. Breast, cervical, prostate, renal, lung, colon, liver, pancreatic, oesophageal, gastric, laryngeal, thyroid, parathyroid, bladder and ovarian cancers. Also, melanoma, cylindroma, squamous cell carcinoma (skin, and head and neck), oral carcinoma, endometrial carcinoma, retinoblastoma and astrocytoma/glioblastoma. and secretion (for example, Il6, TnFα and BAFF) by BMSCs, which in turn promote multiple myeloma cell growth and survival 53, 54 through paracrine mechanisms. nFκB activation also has important roles in some clinical manifestations of multiple myeloma. This includes the formation of osteolytic lesions in about 70% of patients with this condition, which occurs mostly through receptor activator of nFκB (RAnK)/RAnK ligand (RAnKl) mediated nFκB activation in osteoclasts 50 . osteoclasts in turn secrete soluble factors (for example, matrix metalloproteinases, bone morphogenetic protein (BMP) and insulinlike growth factor 1 (IGF1)) that contribute to bone metastases and multiple myeloma cell proliferation and survival [55] [56] [57] . 58, 59 . Although bortezomib affects other signalling pathways, its efficacy may in part be due to inhibition of nFκB activity [60] [61] [62] . In addition, geneexpression profiling using microarrays allowed the identification of a subgroup of multiple myeloma cells that have an nFκB signature that characterizes them as being more sensitive to bortezomib 63 . Thalidomide (Thalomid; Celgene), lenalidomide (Revlimid; Celgene) and arsenic trioxide (Trisenox; Cephalon) are also active against multiple myeloma 64, 65 . Although they can inhibit nFκB, it is not clear whether their clinical activity is due to nFκB inhibition.
Genetic evidence. Beyond these observations, the most striking evidence that validates nFκB as a crucial player in the pathogenesis of multiple myeloma came from two recent studies that have led to the identification of mutations in genes encoding regulators of nFκB signalling pathways 66, 67 . Two laboratories used multipronged genomic and geneexpression profiling approaches to identify nFκBactivating mutations in onefifth of several hundred multiple myeloma cell lines and patient samples. Gainoffunction mutations were identified in genes encoding positive regulators of nFκB signalling, including NIK, NFKB1 (encoding p105/p50), and NFKB2 (encoding p100/p52). Three receptors of the TnF receptor (TnFR) superfamily, CD40, lTβ receptor (LTBR) and TACI (also known as TNFRSF13B), were also identified (FIG. 2) . lossoffunction mutations occurred in genes encoding negative regulators of nFκB activity, including TnFRassociated factor 2 (TRAF2; a negative regulator of the alterna tive nFκB pathway but a positive regulator of the classical nFκB pathway), TRAF3, cIAP1/2 and CylD (FIG. 2) . Most of these genetic alterations result in the activation of both the classical and alternative nFκB pathways as evaluated by p100 processing, p52 nuclear localization, IκBα phosphory lation, increased RelA, p50, RelB and p52 DnAbinding activity, and increased nFκB target gene expression 66, 67 .
niK stabilization and nF-κB activation one major consequence of the detected mutations in multiple myeloma cells is the stabilization of nIK. The high constitutive amounts of nIK protein in multiple mye loma were shown to activate both classical and alternative nFκB signalling, and to be required for multiple myeloma cell growth and survival 66, 67 .
normally, nIK is rapidly degraded in nonstimulated cells, and this degradation is required to keep nIK activity at a low basal level [68] [69] [70] . Recent work indicates that nIK degradation in resting cells depends on its association with TRAF3, which serves as an adaptor that recruits nIK to a ubiqu itin ligase complex composed of TRAF2 and cIAP1/2 (REF. 71 ). within this complex, cIAP1 and cIAP2 are directly responsible for the degradative K48linked polyubiquityl ation of nIK 72, 73 . Receptor (for example, CD40, lTβR or BAFFR) engagement results in the recruitment of the TRAF3-TRAF2-cIAP1/2 complex to the receptor, which leads to the rapid activation of TRAF2. This in turn ubiquitylates cIAP1/2 via a nondegradative K63linkage and thereby enhances their ubiquitin ligase activity, which is now directed towards TRAF3. This then leads to the K48linked ubiquityl ation and eventual degradation of TRAF3 (REF. 71 ). once TRAF3 is degraded, nIK can no longer interact with the TRAF2-cIAP1/2 complex, resulting in the stabilization of newly synthesized nIK and its eventual autophosphorylation and activation.
nIK overexpression due to amplification or translocation of the NIK locus, or enhanced stability due to aminoacid ; see also . A20, zinc finger protein A20 (also known as TNFAIP3); BCL2, B-cell lymphoma protein 2; BCL-X L , also known as BCL2-like 1; BFL1, also known as BCL2A1; CDK2, cyclin-dependent kinase 2; COX2, cyclooxygenase 2; CXCL, chemokine (C-X-C motif) ligand; DR, death receptor; eLAM1, endothelial adhesion molecule 1; FLIP, also known as CASP8; GADD45β, growth arrest and DNA-damage-inducible protein β; HIF1α, hypoxia-inducible factor 1α; ICAM1, intracellular adhesion molecule 1; IeX-1L, radiation-inducible immediate early gene (also known as IeR3); IL, interleukin; iNOS, inducible nitric oxide synthase; KAL1, Kallmann syndrome 1 sequence; MCP1, monocyte chemoattractant protein 1 (also known as CCL2); MIP2, macrophage inflammatory protein 2; MMP, matrix metalloproteinase; MnSOD, manganese superoxide dismutase (also known as SOD2); TNF, tumour necrosis factor; TRAF, TNF receptorassociated factor; uPA, urokinase plasminogen activator; VCAM1, vascular cell adhesion molecule 1; VeGF, vascular endothelial growth factor; XIAP, X-linked inhibitor of apoptosis protein. substitutions that disrupt the ability of nIK to bind TRAF3, occur in multiple myeloma 66, 67 . In addition, many multiple myeloma cells carry TRAF3inactivating mutations and demonstrate accumulation of nIK 66, 67 . Importantly, 90% of patients with low TRAF3 levels respond to bortezomib, with a significant increase in survival 67 .
Collectively, these results suggest that stabilization of nIK, and subsequent nFκB activation, is associated with bortezomib sensitivity and increased survival. other mutations that lead to nIK stabilization include deletions of the linked cIAP1 and cIAP2 loci, and loss of TRAF2 66, 67 . The phenotypic consequences of all of these mutations seem to be similar.
Based on our current knowledge, it was not surprising to find that nIK stabilization results in the constitutive activation of the alternative nFκB pathway and increased Bcell survival. Analysis of alymphoplasia (aly) mice, which express a nonfunctional nIK mutant, revealed an autonomous Bcell defect and inability to activate the alternative nFκB pathway -a defect that is also exhibited in nIKdeficient cells [74] [75] [76] [77] . Moreover, induction of the alternative nFκB signalling pathway, especially in response to BAFF and CD40l, is crucial for normal Bcell survival 36, 37, 78, 79 . TRAF3 and TRAF2 both behave as negative regulators of Bcell survival downstream of BAFFR, in part via the suppression of nFκB2/ p100 processing 80 . Finally, it has been reported that increased expression of nIK in primary B cells, especially a nonTRAF3 binding mutant, leads to expansion of the Bcell compartment and extended Bcell survival 104 . Together, these data suggest that in response to BAFF and CD40l, the activation of the alternative nFκB pathway via nIK stabilization is crucial for Bcell survival.
However, recent work by Staudt and colleagues revealed that inhibition of IKKα, the physiological target for nIK, had no effect on multiple myeloma cell survival, whereas inhibition of IKKβ by the specific inhibitor Mln120B did 66 . The control of classical nFκB signalling by nIK overexpression seems puzzling. Based on the characterization of aly mice as well as of Nikknockout mice, it was suggested that nIK does not participate in the activation of the classical nFκB path way downstream of TnFR in normal cells 77 . nonetheless, nIK overexpression is known to activate the classical nFκB 81 pathway, and therefore nIK accumulation in cancer cells results in the aberrant participation of nIK in activation of the classical nFκB pathway. It should also be noted that nIK is required for the activation of both the classical and alternative nFκB pathways in response to CD40l and BAFF in Burkitt lymphoma derived lymphoblastoid cells 82 . In summary, these observations lead to the conclusion that nIK overexpression is an important marker and driver of malignant plasma B cells and that nIKinduced IKKβ activation is required for uncontrolled Bcell growth. Consequently, nIK is an attractive target for therapeutic intervention.
iAp antagonists and nF-κB activation nIK overexpression was detected in multi ple myeloma cells that have intact TRAF3 and instead have genetic abnormalities that prevent the expression of cIAP1 and cIAP2 (REFs 66, 67) . These observations provided the first clue that cIAP1 and cIAP2 have a See main text for further details. cIAP, inhibitor of apoptosis protein; P, phosphate; p100, encoded by NFKB2, precursor to p52; p105, encoded by NFKB1, precursor to p50; ReLA, p65; TAK1, transforming growth factor-β-activated kinase 1 (also known as MAP3K7); TRAF, TNF receptor-associated factor.
negative role in the control of nIK stability. As discussed above, it is now clear that cIAP1 and cIAP2 are the ubiquitin ligases that target nIK for degradation. Consequently, IAP antagonists can induce nIK stabilization and lead to strong induc tion of classical and alternative nFκB signalling 72, 73 . However, the role of cIAP1 and cIAP2 in nFκB regulation and function is more com plex. nFκB suppresses apoptosis by induc ing the expression of a number of genes whose products inhibit apoptosis, including cIAP1 and cIAP2 (REF. 83 ). cIAP1 and cIAP2 belong to the IAP family that has eight mem bers in humans: cIAP1 and cIAP2, XIAP, nAIP (neuronal IAP), MlIAP (melanoma IAP), TsIAP (testisspecific IAP), BRUCe (BIRcontaining ubiquitin conjugating enzyme) and survivin 84, 85 . By virtue of their interaction with TRAF2, cIAP1 and cIAP2 are recruited to TnFR1 and TnFR2 signal ling complexes where they negatively modu late caspase 8 activity 83, [86] [87] [88] . cIAP1 and cIAP2 are also RInG domaincontaining ubiquitin ligases that are capable of promoting ubiqu itylation and proteasomal degradation of themselves and several of their binding partners, such as TRAF2 (REFs 84, 89, 90) and TRAF3 (REF. 91 ). Mice deficient in cIAP1 or cIAP2 do not reveal any significant devel opmental abnormalities or malfunctions in the apoptotic processes 92, 93 , which suggests that either these proteins are not important during normal development or that the two are redundant. By contrast, overexpression of cIAP1 and cIAP2 has been implicated in tumour cell survival 85 , and genetic amplifi cation of cIAP1 was suggested to promote tumorigenesis and sustain tumour growth in a mouse model of liver cancer 94 . The antiapoptotic activity of IAPs is counteracted by the natural mammalian IAP antagonist SMAC/DIABlo (second mitochondrial activator of caspases/direct IAP binding protein with low pI), which is released from mitochondria into the cyto plasm upon apoptosis induction 95, 96 . Several IAP antagonists that mimic the interaction of SMAC with IAPs have been developed and are collectively called SMAC mimics. These compounds promote apoptosis of various cancer cells, including multiple myeloma cells, either as single agents or in synergy with other proapoptotic stimuli such as TnFα [97] [98] [99] . Their efficacy was also demonstrated in a human multiple myeloma xenograft mouse model 98 . This activity is perplexing, as several recent reports established that IAP antago nists also induced the activation of both the classical and alternative nFκB pathways 72, 73 , a complex twist that might limit their use as cancer therapeutics. IAP antagonists induce IκBα phosphorylation, p100 processing and expression of several nFκBdependent genes, including TNFα, IL8 and monocyte chemoattractant protein 1 (MCP1; also known as CCL2) 72, 73 . Importantly, although blockade of TnFα signalling suppressed IAP antagonistinduced cell death, it had no effect on nFκB activation induced by the same molecule 72 . It was shown that IAP antagonists induced nIK stabilization through inhibition of cIAP1dependent and cIAP2dependent nIK ubiquitylation and proteasomal degradation. It was also dem onstrated that TRAF2 is a crucial scaffolding link between cIAP1 and nIK. Cell stimula tion with known inducers of the alternative nFκB pathway, such as TweAK, triggered the degradation of cIAP1 and cIAP2, and the concomitant stabilization of nIK and p100 processing 72 . However, when CD40l and BAFF were used, no ligandinduced cIAP1/2 degradation could be detected under condi tions in which cIAP1/2induced TRAF3 degradation and nIK stabilization were readily observed 71 . Together, these data confirm that cIAP1 and cIAP2 are the e3 ubiquitin ligases responsible for nIK degradation, and are therefore vital regulators of alternative nFκB signalling. As nIK accumulation seems to be equally important for activation of the classical nFκB pathway in cancer cells (see above), it would be interesting to examine whether IAP antagonists also induce nIKdependent activation of the classical nFκB pathway in vivosomething that would compromise their therapeutic potential. The dual role of IAP antagonists in inducing apoptosis while activating nFκB is presented in FIG. 3 . It seems that the proapoptotic activity of these compounds is limited to a small number of unique cancer cell lines 73 . Indeed, in many other cases these com pounds would actually activate nFκB signalling upon nIK stabilization and at the same time also prevent jnK activation 91 . So, the net effect may be inhibition of apop tosis rather than induction of apoptosis.
what lessons can we learn from these data? First, the recent findings regarding the full biochemical effects of cIAP1 and cIAP2 inhibition allows a better understanding of the complex mechanisms that control nIK stability and other aspects of TnFR signal ling. we propose the following model: in the absence of stimuli, TRAF3 associates with cytoplasmic nIK and subsequently targets it to e3 complexes containing TRAF2, cIAP1 and cIAP2, which mark nIK for proteasomal degradation. Upon receptor stimulation, these regulators will be sequestered at the cytoplasmic portion of the receptor, resulting in TRAF2 activation, enhanced cIAP1 and cIAP2 activity and TRAF3 degradation, thereby leading to nIK stabilization. Any mutation affecting the binding of these regulators to each other and to nIK would result in nIK stabilization. SMAC mimics or IAP antagonists have the same effect. overexpression of nIK in turn leads to constitutive activation of the classical and alternative nFκB pathways, and an increase in Bcell growth and survival. The remark able activity of bortezomib in patients with multiple myeloma, especially in those with TRAF3 inactivation, supports the key role of nFκB in the pathogenesis of this condition.
Second, as nIK stabilization seems to be a new marker for malignant B cells, we believe that the specific targeting of nIK may be particularly effective in the treatment of multiple myeloma and potentially other Bcell malignancies. IKKβ inhibitors should also be effective owing to its increased activity in cells in which nIK is persistently activated.
Third, it is questionable whether IAP antagonists will find use as cancer thera peutics, unless they can selectively induce apoptosis in a broad spectrum of cancer cells despite their proven ability to stabilize nIK and thereby induce nFκB activation. Further preclinical studies and clinical trials will be needed to define the true potential of SMAC mimics as anticancer drugs.
nF-κB inhibitors in cancer therapy
The discovery of genetic alterations that lead to constitutive nFκB activation in onefifth of patients with multiple myeloma provides a strong rationale for the use of nFκB inhibitors as singleagent therapeutics in this malignancy. It also supports the idea that genomic technology should become an integral part of prospective clinical trials, which would help identify which molecularly defined subsets of patients will preferentially respond to nFκB inhibi tion. Indeed, a major challenge for cancer researchers and clinicians is how to identify those patients that are most likely to benefit from nFκB inhibition.
Beyond multiple myeloma, cancer genetics and genomics approaches have been success ful in identifying a subgroup of diffuse large Bcell lymphoma on the basis of the nFκB signature of geneexpression profiles, and preclinical studies have validated nFκB as . In addition, carboxyterminal truncated forms of p100 have been detected in several lymphomas and leukaemias, including cutaneous Tcell lymphoma and Bcell chronic lymphocytic leukaemia 101 . In all cases, these mutations result in nuclear p52 accumulation, therefore indicating that these types of cancer should also benefit from nFκB inhibition. The question, however, is which of the two nFκB signal ling pathways should be targeted in these malignancies: the classical or the alternative? The nFκB geneexpression signature of patients should provide a better prediction for the choice of inhibition, and also allow the development of diagnostic and prog nostic biomarkers of the response to nFκB inhibition. Based on multiple myeloma studies, nIK is an attractive candidate for inhibition, but not in those cases in which processing of truncated p100 variants is nIK independent. Together, coupling biomarkers with pathwaytargeted therapeutics should ultimately allow the treatment of patients with cancer to be tailored to their unique genetic abnormalities.
Much effort has been made by the phar maceutical industry to develop IKKβ and other nFκB inhibitors 102 . However, IKKα inhibitors are yet to be described. An ideal IKK/nFκB inhibitor to be used in molecu larly targeted therapy should prevent nFκB activation without any effects on other sig nalling pathways, and should be more active in malignant cells than in normal cells. one should also consider that excessive and pro longed nFκB inhibition can be detrimental owing to its important role in innate immu nity. Thus, although highly efficient nFκB inhibition is desired during administration of conventional anticancer drugs, nFκB inhibition should be transient and reversible to avoid longterm immunosuppression. In addition, by selectively targeting specific nFκB signalling components involved in a particular disease, one may expect to minimize systemic toxicity and avoid broad suppression of innate immunity. Finally, the dose and schedule for delivering the com pound needs to be carefully evaluated as a single agent, and its efficacy has to be deter mined in combination with other anticancer agents. Several reports have documented the efficacy of IKK/nFκB inhibitors in trigger ing apoptosis in cancer cells as single agents, and in combination either with death inducing cytokines or chemotherapeutic drugs. As this area of research is moving at a rapid pace, there is hope that it will be learnt how to use such compounds in the clinic. However, one major pitfall that will have to be addressed before antiIKK or nFκB therapies can become successful is the sur prising but pronounced ability of inhibitors of nFκB activation to enhance the produc tion of Il1β and related cytokines owing to excessive inflammasome activation during bacterial infections 103 . This adverse effect is due to the ability of nFκB to promote the expression of genes whose products control Il1β processing and secretion. Perhaps the only way to avoid such complications would be to use IKK and nFκB inhibitors for only a short duration in combination with broad spectrum antibiotics under wellcontrolled hospital conditions. Inhibitor of apoptosis protein (IAP) antagonists induce cIAP1 and cIAP2 proteasomal degradation, thereby leading to activation of the classical and alternative NF-κB signalling pathways through stabilization of NF-κB-inducing kinase (NIK). IAP antagonists also induce tumour-necrosis factor α (TNFα)-dependent cell death by counteracting the inhibitory activity of cIAP1/2 and XIAP on the caspase cascade. See main text for further details. A20, zinc finger protein A20 (also known as TNFAIP3); BCL2, B-cell lymphoma protein 2; BCL-X L , also known as BCL2-like 1; FADD, Fas (TNFRSF6)-associated via death domain; FLIP, also known as CASP8; IKK, IκB kinase; P, phosphate; p50, encoded by NFKB1; p100, encoded by NFKB2, precursor to p52; ReLA, p65; RIP1, receptor interacting protein 1; TRADD, TNF receptor type 1 associated death domain protein; TRAF, TNF receptor-associated factor; U, ubiquitin; XIAP, X-linked IAP.
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